Header Logo

Connection

DAVID GRAHAM to Drug Therapy, Combination

Back to Details
This is a "connection" page, showing publications DAVID GRAHAM has written about Drug Therapy, Combination.
DAVID GRAHAM
Connection Strength
8.193
Drug Therapy, Combination
  1. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011 Apr; 16(2):146-52.
    View in: PubMed
    Score: 0.282
  2. Overcoming the effects of increasing antimicrobial resistance on Helicobacter pylori therapy. Expert Rev Gastroenterol Hepatol. 2024 Nov; 18(11):705-711.
    View in: PubMed
    Score: 0.182
  3. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol. 2025 Apr 01; 120(4):787-798.
    View in: PubMed
    Score: 0.179
  4. Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates. Dig Dis Sci. 2023 05; 68(5):1691-1697.
    View in: PubMed
    Score: 0.161
  5. Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert Rev Gastroenterol Hepatol. 2023 03; 17(3):311.
    View in: PubMed
    Score: 0.161
  6. How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert Rev Gastroenterol Hepatol. 2023 Jan; 17(1):1-7.
    View in: PubMed
    Score: 0.159
  7. Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta-analysis and critical analysis. Helicobacter. 2023 Feb; 28(1):e12936.
    View in: PubMed
    Score: 0.158
  8. Diagnosis and Treatment of Helicobacter pylori Infection. Annu Rev Med. 2022 01 27; 73:183-195.
    View in: PubMed
    Score: 0.149
  9. Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study. Helicobacter. 2021 Jun; 26(3):e12801.
    View in: PubMed
    Score: 0.141
  10. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol. 2021 01 01; 116(1):1-3.
    View in: PubMed
    Score: 0.139
  11. Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy. Helicobacter. 2021 Feb; 26(1):e12773.
    View in: PubMed
    Score: 0.138
  12. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial. Ann Intern Med. 2020 06 16; 172(12):795-802.
    View in: PubMed
    Score: 0.132
  13. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Dig Dis Sci. 2020 12; 65(12):3639-3646.
    View in: PubMed
    Score: 0.130
  14. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther. 2000 Feb; 14(2):211-5.
    View in: PubMed
    Score: 0.130
  15. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter. 2019 Feb; 24(1):e12554.
    View in: PubMed
    Score: 0.120
  16. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018 09; 16(9):679-687.
    View in: PubMed
    Score: 0.118
  17. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2018 09; 16(9):1427-1433.
    View in: PubMed
    Score: 0.115
  18. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology. 2018 07; 155(1):67-75.
    View in: PubMed
    Score: 0.114
  19. Update on the Use of Vonoprazan: A Competitive Acid Blocker. Gastroenterology. 2018 Feb; 154(3):462-466.
    View in: PubMed
    Score: 0.113
  20. Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection. Clin Gastroenterol Hepatol. 2018 09; 16(9):1531-1532.
    View in: PubMed
    Score: 0.113
  21. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan; 33(1):37-56.
    View in: PubMed
    Score: 0.113
  22. Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now? Saudi J Gastroenterol. 2017 Sep-Oct; 23(5):265-267.
    View in: PubMed
    Score: 0.110
  23. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Dig Dis Sci. 2017 08; 62(8):1890-1896.
    View in: PubMed
    Score: 0.108
  24. Update on Helicobacter pylori research. Eradication. Eur J Gastroenterol Hepatol. 1997 Jun; 9(6):626-8.
    View in: PubMed
    Score: 0.108
  25. It is time to rethink H. pylori therapy. J Gastrointestin Liver Dis. 2017 06; 26(2):115-117.
    View in: PubMed
    Score: 0.108
  26. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017 07; 14(7):383-384.
    View in: PubMed
    Score: 0.108
  27. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med. 2017 Apr; 84(4):310-318.
    View in: PubMed
    Score: 0.107
  28. Increasing role for modified bismuth-containing quadruple therapies for Helicobacter pylori eradication. Minerva Gastroenterol Dietol. 2017 06; 63(2):77-79.
    View in: PubMed
    Score: 0.105
  29. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Dig Dis Sci. 2016 11; 61(11):3215-3220.
    View in: PubMed
    Score: 0.103
  30. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016 06; 14(6):577-85.
    View in: PubMed
    Score: 0.100
  31. Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut. 2017 02; 66(2):384-386.
    View in: PubMed
    Score: 0.100
  32. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016 May; 65(5):870-8.
    View in: PubMed
    Score: 0.099
  33. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016 05; 150(5):1113-1124.e5.
    View in: PubMed
    Score: 0.099
  34. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol. 2015 Dec 07; 21(45):12954-62.
    View in: PubMed
    Score: 0.098
  35. Helicobacter pylori: New Thoughts and Practices. Gastroenterol Clin North Am. 2015 Sep; 44(3):xv-xvi.
    View in: PubMed
    Score: 0.095
  36. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am. 2015 Sep; 44(3):537-63.
    View in: PubMed
    Score: 0.094
  37. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century. World J Gastroenterol. 2014 Sep 07; 20(33):11467-85.
    View in: PubMed
    Score: 0.089
  38. High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter. 2014 Aug; 19(4):319-22.
    View in: PubMed
    Score: 0.087
  39. Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Curr Pharm Des. 2014; 20(28):4510-6.
    View in: PubMed
    Score: 0.085
  40. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol. 2014 Jan; 8(1):21-8.
    View in: PubMed
    Score: 0.085
  41. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013 Oct; 25(10):1134-40.
    View in: PubMed
    Score: 0.084
  42. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):177-86.e3; Discussion e12-3.
    View in: PubMed
    Score: 0.082
  43. Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth. Aliment Pharmacol Ther. 1993 Feb; 7(1):111-3.
    View in: PubMed
    Score: 0.080
  44. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter. 2012 Oct; 17(5):382-90.
    View in: PubMed
    Score: 0.077
  45. Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol. 2012 Jan; 27(1):59-61.
    View in: PubMed
    Score: 0.074
  46. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter. 2011 Aug; 16(4):295-300.
    View in: PubMed
    Score: 0.072
  47. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2011 Apr; 45(4):309-13.
    View in: PubMed
    Score: 0.071
  48. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011 Apr; 16(2):139-45.
    View in: PubMed
    Score: 0.071
  49. Empiric therapies for Helicobacter pylori infections. CMAJ. 2011 Jun 14; 183(9):E506-8.
    View in: PubMed
    Score: 0.070
  50. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011 Feb; 8(2):79-88.
    View in: PubMed
    Score: 0.070
  51. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am. 2010 Sep; 39(3):465-80.
    View in: PubMed
    Score: 0.068
  52. Helicobacter pylori infection. N Engl J Med. 2010 08 05; 363(6):595-6; author reply 596.
    View in: PubMed
    Score: 0.067
  53. Helicobacter pylori eradication therapy research: Ethical issues and description of results. Clin Gastroenterol Hepatol. 2010 Dec; 8(12):1032-6.
    View in: PubMed
    Score: 0.067
  54. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug; 59(8):1143-53.
    View in: PubMed
    Score: 0.067
  55. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol. 2010 Aug; 45(8):816-20.
    View in: PubMed
    Score: 0.065
  56. Clinical practice: diagnosis and evaluation of dyspepsia. J Clin Gastroenterol. 2010 Mar; 44(3):167-72.
    View in: PubMed
    Score: 0.065
  57. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008 Jun; 5(6):321-31.
    View in: PubMed
    Score: 0.058
  58. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008; 68(6):725-36.
    View in: PubMed
    Score: 0.056
  59. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007 Aug; 12(4):275-8.
    View in: PubMed
    Score: 0.055
  60. One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm. Gut. 2007 Jul; 56(7):1021-3; author reply 1022-3.
    View in: PubMed
    Score: 0.054
  61. Failures in a proton pump inhibitor therapeutic substitution program: lessons learned. Dig Dis Sci. 2007 Oct; 52(10):2813-20.
    View in: PubMed
    Score: 0.053
  62. Helicobacter pylori eradication and its effect on iron stores: a reappraisal. J Infect Dis. 2006 Sep 01; 194(5):714; author reply 715-6.
    View in: PubMed
    Score: 0.051
  63. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther. 2006 Sep 01; 24(5):845-50.
    View in: PubMed
    Score: 0.051
  64. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther. 2005 Jan 15; 21(2):165-8.
    View in: PubMed
    Score: 0.046
  65. Effects of amoxicillin dosage on cure rate, gut microbiota, and?antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial. Lancet Microbe. 2025 Mar; 6(3):100975.
    View in: PubMed
    Score: 0.046
  66. Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti Infect Ther. 2004 Aug; 2(4):599-610.
    View in: PubMed
    Score: 0.044
  67. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis. 2004 Jun; 36(6):384-7.
    View in: PubMed
    Score: 0.044
  68. A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran. Helicobacter. 2024 Jan-Feb; 29(1):e13061.
    View in: PubMed
    Score: 0.043
  69. Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One. 2023; 18(11):e0294403.
    View in: PubMed
    Score: 0.042
  70. Eradicating Helicobacter pylori via 13C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method. Gut. 2023 11 24; 72(12):2231-2240.
    View in: PubMed
    Score: 0.042
  71. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter. 2023 Dec; 28(6):e13019.
    View in: PubMed
    Score: 0.042
  72. Controversies regarding management of Helicobacter pylori infections. Curr Opin Gastroenterol. 2023 11 01; 39(6):482-489.
    View in: PubMed
    Score: 0.042
  73. The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials. Gastroenterology. 2003 Aug; 125(2):639; author reply 640-1.
    View in: PubMed
    Score: 0.041
  74. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003 May 15; 17(10):1229-36.
    View in: PubMed
    Score: 0.041
  75. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
    View in: PubMed
    Score: 0.040
  76. NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med. 2002 Dec 26; 347(26):2162-4.
    View in: PubMed
    Score: 0.040
  77. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology. 2021 08; 161(2):495-507.e4.
    View in: PubMed
    Score: 0.035
  78. Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance. Aliment Pharmacol Ther. 2001 Apr; 15(4):513-8.
    View in: PubMed
    Score: 0.035
  79. Antibiotic-resistant H. pylori infection and its treatment. Curr Pharm Des. 2000 Oct; 6(15):1537-44.
    View in: PubMed
    Score: 0.034
  80. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther. 2000 Jun; 14(6):745-50.
    View in: PubMed
    Score: 0.033
  81. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter. 2020 Aug; 25(4):e12692.
    View in: PubMed
    Score: 0.033
  82. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera? or Lactobacillus reuteri for treatment na?ve or for retreatment of Helicobacter pylori. Two randomized pilot studies. Helicobacter. 2019 Dec; 24(6):e12659.
    View in: PubMed
    Score: 0.032
  83. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999 Jul 20; 131(2):88-95.
    View in: PubMed
    Score: 0.031
  84. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter. 1999 Jun; 4(2):106-12.
    View in: PubMed
    Score: 0.031
  85. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial. Helicobacter. 2019 Aug; 24(4):e12596.
    View in: PubMed
    Score: 0.031
  86. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019 06; 49(11):1385-1394.
    View in: PubMed
    Score: 0.031
  87. Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. Aliment Pharmacol Ther. 1999 Feb; 13(2):169-72.
    View in: PubMed
    Score: 0.030
  88. Diagnosis and management of Helicobacter pylori infection. Clin Cornerstone. 1999; 1(5):18-28.
    View in: PubMed
    Score: 0.030
  89. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? J Dig Dis. 2018 Nov; 19(11):674-677.
    View in: PubMed
    Score: 0.030
  90. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen,?or?Ibuprofen. J Am Coll Cardiol. 2018 04 24; 71(16):1741-1751.
    View in: PubMed
    Score: 0.029
  91. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018 06; 47(11):1453-1463.
    View in: PubMed
    Score: 0.029
  92. One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. Dig Dis Sci. 1998 Mar; 43(3):464-7.
    View in: PubMed
    Score: 0.028
  93. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Oct; 11(5):935-8.
    View in: PubMed
    Score: 0.028
  94. Successful low-dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole-resistant Helicobacter pylori. Aliment Pharmacol Ther. 1997 Jun; 11(3):523-7.
    View in: PubMed
    Score: 0.027
  95. High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1996 Dec; 10(6):1001-4.
    View in: PubMed
    Score: 0.026
  96. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 01; 66(1):6-30.
    View in: PubMed
    Score: 0.026
  97. One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1996 Aug; 10(4):617-21.
    View in: PubMed
    Score: 0.026
  98. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Aliment Pharmacol Ther. 1996 Feb; 10(1):119-22.
    View in: PubMed
    Score: 0.025
  99. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015 Nov; 64(11):1715-20.
    View in: PubMed
    Score: 0.024
  100. Treatment of Helicobacter pylori infection with omeprazole-amoxicillin combination therapy versus ranitidine/sodium bicarbonate-amoxicillin. Am J Gastroenterol. 1995 Sep; 90(9):1411-4.
    View in: PubMed
    Score: 0.024
  101. Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection. Am J Gastroenterol. 1995 Sep; 90(9):1415-8.
    View in: PubMed
    Score: 0.024
  102. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1995 Apr; 9(2):209-12.
    View in: PubMed
    Score: 0.023
  103. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth. Am J Gastroenterol. 1995 Mar; 90(3):403-5.
    View in: PubMed
    Score: 0.023
  104. Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1994 Aug; 8(4):453-6.
    View in: PubMed
    Score: 0.022
  105. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol. 1994 Aug; 89(8):1203-5.
    View in: PubMed
    Score: 0.022
  106. Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1994 Apr; 8(2):259-62.
    View in: PubMed
    Score: 0.022
  107. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014 Jun; 19(3):207-13.
    View in: PubMed
    Score: 0.022
  108. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol. 1993 Nov; 28(11):939-42.
    View in: PubMed
    Score: 0.021
  109. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol. 1993 Jun; 24(6):577-83.
    View in: PubMed
    Score: 0.020
  110. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013 Oct; 18(5):373-7.
    View in: PubMed
    Score: 0.020
  111. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992 May 01; 116(9):705-8.
    View in: PubMed
    Score: 0.019
  112. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May; 61(5):646-64.
    View in: PubMed
    Score: 0.019
  113. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb; 102(2):493-6.
    View in: PubMed
    Score: 0.019
  114. Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacter pylori infection: the example of combined bismuth subsalicylate and nitrofurantoin. Am J Gastroenterol. 1991 Sep; 86(9):1158-62.
    View in: PubMed
    Score: 0.018
  115. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med. 1991 Aug 15; 115(4):266-9.
    View in: PubMed
    Score: 0.018
  116. Double-blind randomized trial of quadruple sequential Helicobacter pylori eradication therapy in asymptomatic infected children in El Paso, Texas. J Pediatr Gastroenterol Nutr. 2011 Mar; 52(3):319-25.
    View in: PubMed
    Score: 0.018
  117. Helicobacter pylori eradication and change in markers of iron stores among non-iron-deficient children in El Paso, Texas: an etiologic intervention study. J Pediatr Gastroenterol Nutr. 2011 Mar; 52(3):326-32.
    View in: PubMed
    Score: 0.018
  118. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. Am J Gastroenterol. 1990 Apr; 85(4):394-8.
    View in: PubMed
    Score: 0.016
  119. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009 Apr; 14(2):109-18.
    View in: PubMed
    Score: 0.015
  120. Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. Aliment Pharmacol Ther. 2006 Jan 15; 23(2):295-301.
    View in: PubMed
    Score: 0.012
  121. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003 Dec; 8(6):626-42.
    View in: PubMed
    Score: 0.011
  122. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter. 2003 Aug; 8(4):307-9.
    View in: PubMed
    Score: 0.010
  123. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol. 2002 Apr; 97(4):857-60.
    View in: PubMed
    Score: 0.009
  124. Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1998 Jul; 12(7):635-9.
    View in: PubMed
    Score: 0.007
  125. Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular? Am J Clin Pathol. 1997 Nov; 108(5):504-9.
    View in: PubMed
    Score: 0.007
  126. Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. Aliment Pharmacol Ther. 1997 Oct; 11(5):939-42.
    View in: PubMed
    Score: 0.007
  127. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Jun; 11(3):529-32.
    View in: PubMed
    Score: 0.007
  128. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter. 1996 Dec; 1(4):243-50.
    View in: PubMed
    Score: 0.007
  129. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995 Aug 15; 123(4):241-9.
    View in: PubMed
    Score: 0.006
  130. Infectious esophagitis. Gastrointest Endosc Clin N Am. 1994 Oct; 4(4):713-29.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.